A history of viral encephalitis is one of the strongest risk factors for developing dementia. With @JacobJacobog02, Yifan Chen, @RNA_Life, and @RyanDhindsa, we refine this link by describing a neuronal cell type that can reactivate HSV-1 in humans 1/n biorxiv.org/content/10.64898…

This is totally out of control: There’s 0 - I repeat 0 - evidence any of the LLM work did anything meaningful for Rosie’s cancer I’m sorry to rain on the parade here. I know we want to believe. But, it’s possible to do a lot of things and have nothing happen @paul_conyngham co-administered α-PD-1 (conventional immunotherapy) with a TKI and the mRNA. It’s probably the most effective cancer immunotherapy of all time. This isn’t a small detail! There’s no evidence his process (beyond FDA approved doggie α-PD-1) had any impact on disease progression. The most parsimonious explanation is a partial response to α-PD-1 I get it. The chat bots make for a great story (although checking multiple LLMs isn’t validation), but it’s really just a neat story. It’s fundraising copy. Before he starts selling the “custom neoantigen mRNA vax” story to consumers, he should provide some evidence it did anything! That’s responsible citizen science This is just storytelling for the AGI true believers. Specifically, a story in search of venture money

Let’s talk about rare variant association tests - we have a new method that helps you discover more with the same data! It’s called FlexRV to signal our approach: Flexibly modeling rare variant pathogenicity improves gene discovery for complex traits. biorxiv.org/content/10.1101/…

Thank you @chenweng1991, @jswlab, @bloodgenes for the feedback on our work. @LeifLudwig and I agree that the “-2” filtering method that mitigates edge bias is a critical development for ReDeeM. Nevertheless, we stand by our original preprint, noting the following: 1/n

Simplifying causal gene identification in GWAS loci medrxiv.org/cgi/content/shor… #medRxiv

What are you convinced people are pretending to enjoy?